MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).

The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.

MaaT Pharma(EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival ...

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem ...

French-based MaaT Pharma is eyeing up a Phase II study of its immune system modulator after its Phase Ib trial in patients with amyotrophic lateral sclerosis (ALS) met all of its primary endpoints.

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival ...

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem ...

This trend is a direct reflection of the continued demand from the medical community for MaaT Pharma’s drug candidate MaaT013. Nomination of Eric Soyer as Chief Financial Officer and transition of ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Maat Pharma is listed on the Euronext Paris trading with ticker code MAAT.PA. It has a market capitalisation of €108.84m, with approximately 13.92m shares in issue. Over the last year ...